Výsledky vyhledávání - Dale E. Shuster
- Zobrazuji výsledky 1 - 10 z 10
-
1
-
2
-
3
Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Autor Giorgio V. Scagliotti, Dale E. Shuster, С. В. Орлов, Joachim von Pawel, Frances A. Shepherd, Jeffrey S. Ross, Qiang Wang, Brian Schwartz, Wallace Akerley
Vydáno 2017Artigo -
4
A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies Autor Sanjay Goel, Alain C. Mita, Monica Mita, Eric K. Rowinsky, Quincy Chu, Nancy Wong, Christopher DesJardins, Fang Fang, Mendel Jansen, Dale E. Shuster, Sridhar Mani, Chris H. Takimoto
Vydáno 2009Artigo -
5
Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors Autor James H. Lewis, Hans Gelderblom, Michiel A. J. van de Sande, Silvia Stacchiotti, John H. Healey, William D. Tap, Andrew J. Wagner, Antonio López‐Pousa, Mihaela Druta, Chia‐Chi Lin, Hideo A. Baba, Youngsook Choi, Qiang Wang, Dale E. Shuster, Sebastian Bauer
Vydáno 2020Artigo -
6
Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors Autor Hans Gelderblom, Andrew J. Wagner, William D. Tap, Emanuela Palmerini, Zev A. Wainberg, Jayesh Desai, John H. Healey, Michiel A. J. van de Sande, Nicholas M. Bernthal, Eric L. Staals, Charles Peterfy, Anna Maria Frezza, Henry H. Hsu, Qiang Wang, Dale E. Shuster, Silvia Stacchiotti
Vydáno 2020Artigo -
7
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locall... Autor Giorgio V. Scagliotti, Joachim von Pawel, Silvia Novello, Rodryg Ramlau, Adolfo Favaretto, Fabrice Barlési, Wallace Akerley, С. В. Орлов, Armando Santoro, David R. Spigel, Vera Hirsh, Frances A. Shepherd, Lecia V. Sequist, Alan N. Sandler, Jeffrey S. Ross, Qiang Wang, Reinhard von Roemeling, Dale E. Shuster, Brian Schwartz
Vydáno 2015Artigo -
8
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib Autor Lorenza Rimassa, Giovanni Abbadessa, Nicola Personeni, Camillo Porta, Ivan Borbath, Bruno Daniele, Stefania Salvagni, Jean‐Luc Van Laethem, Hans Van Vlierberghe, Jörg Trojan, Enrico N. De Toni, Alan Weiss, Steven A. Miles, Antonio Gasbarrini, Monica Lencioni, Maria Lamar, Yunxia Wang, Dale E. Shuster, Brian Schwartz, Armando Santoro
Vydáno 2016Artigo -
9
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane Autor Linda T. Vahdat, Brian Pruitt, Carol J. Fabian, Ragene Rivera, David A. Smith, Elizabeth Tan-Chiu, Jonathan Wright, Antoinette R. Tan, N. D'Acosta, Ellen Chuang, John W. Smith, Joyce O’Shaughnessy, Dale E. Shuster, Nicole Meneses, Kumari Chandrawansa, Fang Fang, Patricia E. Cole, Simon Ashworth, Joanne L. Blum
Vydáno 2009Artigo -
10
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial Autor William D. Tap, Hans Gelderblom, Emanuela Palmerini, Jayesh Desai, Sebastian Bauer, Jean‐Yves Blay, Thierry Alcindor, Kristen N. Ganjoo, Javier Martín‐Broto, Christopher W. Ryan, David M. Thomas, Charles Peterfy, John H. Healey, Michiel A. J. van de Sande, Heather L. Gelhorn, Dale E. Shuster, Qiang Wang, Antoine Yver, Henry H. Hsu, Paul Lin, Sandra Tong-Starksen, Silvia Stacchiotti, Andrew J. Wagner
Vydáno 2019Artigo
Vyhledávací nástroje:
Související témata
Medicine
Internal medicine
Cancer
Gastroenterology
Oncology
Adverse effect
Neutropenia
Pathology
Alternative medicine
Breast cancer
Eribulin
Metastatic breast cancer
Placebo
Randomized controlled trial
Surgery
Chemistry
Chemotherapy
Clinical endpoint
Clinical trial
Confidence interval
Epidermal growth factor receptor
Erlotinib
Erlotinib Hydrochloride
Hazard ratio
Pharmacokinetics
Pharmacology
Physics
Rash
Taxane
Toxicity